Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.
About LivaNova PLC
LivaNova PLC (NASDAQ: LIVN) is a global medical technology company dedicated to improving the lives of patients through innovative healthcare solutions. Headquartered in London, United Kingdom, and with a presence in over 100 countries, LivaNova leverages nearly five decades of expertise to deliver advanced medical devices and therapies that address critical health conditions. The company employs approximately 3,000 professionals worldwide, combining clinical and economic value to serve healthcare providers, systems, and patients.
Core Business Areas
LivaNova operates in two primary business segments:
- Cardiopulmonary Solutions: This segment focuses on technologies that support cardiac surgeries and interventions, including heart-lung machines and oxygenation systems. These products are essential for procedures requiring extracorporeal circulation, enabling healthcare providers to perform complex cardiac surgeries with precision.
- Neuromodulation Devices: LivaNova is a leader in neuromodulation technologies, offering devices designed to treat conditions such as drug-resistant epilepsy and treatment-resistant depression. These solutions provide therapeutic electrical stimulation to targeted areas of the nervous system, improving quality of life for patients with chronic conditions.
Market Presence and Competitive Position
With a significant portion of its revenue derived from the United States (approximately 50%) and Europe (21%), LivaNova maintains a strong foothold in key global markets. The company’s strategic focus on cardiopulmonary and neuromodulation technologies positions it uniquely within the medical technology landscape. Following its formation through the merger of Cyberonics (U.S.) and Sorin (Italy), LivaNova streamlined its business by divesting its cardiac rhythm management and heart valve segments to concentrate on its core competencies.
Value Proposition
LivaNova’s commitment to innovation and patient-centric solutions drives its value proposition. By addressing complex and treatment-resistant medical conditions, the company delivers transformative products that enhance patient outcomes while providing economic value to healthcare systems. Its global reach and diverse product portfolio enable it to meet the needs of a wide range of healthcare providers, from large hospitals to specialized clinics.
Challenges and Industry Dynamics
Operating in the highly regulated medical technology industry, LivaNova faces challenges such as stringent compliance requirements, intense competition, and the need for continuous innovation. The company’s focus on R&D is essential to maintaining its competitive edge, particularly in the rapidly evolving fields of neuromodulation and cardiopulmonary technologies. Additionally, as healthcare systems worldwide demand cost-effective solutions, LivaNova’s ability to demonstrate both clinical efficacy and economic value is critical to its sustained success.
Conclusion
LivaNova PLC stands out as a specialized medical technology company with a clear focus on improving patient outcomes through advanced circulatory support and neuromodulation solutions. Its global presence, robust product portfolio, and dedication to innovation make it a key player in addressing some of the most challenging medical conditions. By prioritizing both clinical and economic value, LivaNova continues to play a pivotal role in transforming modern healthcare.
LivaNova PLC (Nasdaq: LIVN) will host a conference call to discuss its first-quarter 2023 results on May 3, 2023, at 1 p.m. London time (8 a.m. Eastern Time). The results will be released prior to the call, and a live audiocast will be accessible on the company's website. Investors can join by dialing the respective numbers for the U.S. and international callers. The company has nearly five decades of experience in the medical technology sector and operates in over 100 countries. A replay of the call will be available on their website for 90 days.
LivaNova PLC (NASDAQ: LIVN) has received FDA 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM), marking the start of its commercial launch in the U.S. The company also secured approvals from Health Canada and the Japanese PMDA, initiating a broader commercial release in Europe. The Essenz Perfusion System enhances clinical workflows and patient care during cardiopulmonary bypass (CPB) procedures, featuring reliable technology based on the LivaNova S5™ HLM. Key benefits include individualized patient care, user-friendly interfaces, and robust support worldwide.
LivaNova PLC (Nasdaq: LIVN) has announced that its Chief Executive Officer, Damien McDonald, will participate in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The event is scheduled for 9 a.m. Eastern Time on Thursday, March 16. Interested parties can register for the webcast through www.livanova.com/events, with a replay available on the company's website for 90 days after the presentation. LivaNova is a global medical technology company dedicated to improving patient outcomes with innovative solutions.
LivaNova PLC (Nasdaq: LIVN) reported Q4 2022 revenue of $274.9 million, up 1.8% year-over-year, with adjusted diluted EPS at $0.81. For full-year 2022, revenue was $1.02 billion, down 1.3%, but showed a 2.3% rise when excluding the Heart Valve business divested in 2021. The Cardiopulmonary segment grew 10.5%, driven by increased cardiac surgeries. However, Advanced Circulatory Support revenue fell 29.1% due to fewer ECMO treatments. Looking ahead, LivaNova expects 2023 revenue growth of 3-5% and adjusted diluted EPS between $2.45 and $2.65. The company also ceased its heart failure clinical study due to disappointing data.
LivaNova PLC (Nasdaq: LIVN) has initiated a limited commercial release of the Essenz™ Perfusion System in select European centers, following positive clinical experiences at Catharina Hospital in the Netherlands and San Donato Hospital in Italy. The innovative system integrates a next-generation heart-lung machine and a patient monitor, focusing on providing data-driven, personalized support during cardiopulmonary bypass procedures. Both components have received CE Mark, with further regulatory approvals pending in key regions. The release marks a significant advance in perfusion technology, emphasizing safety and operational flexibility.
LivaNova PLC has launched the SenTiva DUO, an implantable pulse generator designed to provide VNS Therapy for drug-resistant epilepsy. This new device features a dual-pin header, allowing existing patients with dual-pin systems to upgrade without lead revision. It maintains the therapeutic advantages of the original SenTiva, including automatic seizure response and programmable therapy options. The device has received 510(k) clearance from the U.S. FDA and is now available in the U.S. market, aiming to enhance patient care for those requiring advanced epilepsy treatment.
LivaNova PLC (NASDAQ: LIVN) will host a conference call on February 22, 2023, at 1 p.m. London time to discuss its fourth-quarter and full-year 2022 results. The results will be released prior to the call. The audiocast can be accessed via www.livanova.com/events. Participants can join via telephone by calling +1 844 200 6205 (U.S.) or +1 929 526 1599 (international), with access code 041577. A replay will be available for 90 days after the call. LivaNova is a global leader in medical technology, focused on delivering innovative solutions for patients and healthcare systems worldwide.
LivaNova PLC (NASDAQ: LIVN) has received a close-out letter from the FDA regarding the Warning Letter issued on December 29, 2015, related to its Munich facility and 3T Heater-Cooler device. This closure signifies the successful implementation of corrective actions by LivaNova. CEO Damien McDonald expressed gratitude for the FDA's collaboration and the efforts of the LivaNova team during this process. The company emphasized its commitment to quality and safety in its operations.
LivaNova PLC (NASDAQ: LIVN) announced its participation in the American Epilepsy Society 2022 Annual Meeting, taking place from December 2-6 in Nashville, Tennessee. The company will showcase seven scientific posters focused on advancing neuromodulation and improving treatment for drug-resistant epilepsy. Dr. Bryan Olin emphasized the company's commitment to enhancing patients' quality of life. Attendees will have the opportunity to engage with presenters about the research findings.
LivaNova PLC (NASDAQ: LIVN) has received 510(k) clearance from the FDA for its LifeSPARC system, enhancing access to extracorporeal membrane oxygenation (ECMO) for hospitals. This new clearance allows ECMO use beyond six hours for patients in acute respiratory or cardiopulmonary failure, including those affected by COVID-19. LifeSPARC aims to simplify ECMO with a user-friendly design, making it suitable for healthcare facilities of all sizes. The company has a strong track record of 100% customer response to recent updates following a recall.
FAQ
What is the current stock price of Livanova Plc (LIVN)?
What is the market cap of Livanova Plc (LIVN)?
What does LivaNova PLC specialize in?
Where is LivaNova PLC headquartered?
What are LivaNova’s main business segments?
How does LivaNova generate revenue?
Who are LivaNova’s competitors?
What makes LivaNova unique in the medical technology industry?
What challenges does LivaNova face in its industry?
What markets does LivaNova primarily serve?
